Last updated 2026-06-18
- Raised $1M grant led by Israel Innovation Authority, Jan 2024
- Raised Seed round led by NFX Capital, Jan 2025
- Raised funding round led by Sapir Venture Partners, Aug 2024
Total raised
$1.0M
Last: Seed 2025-01
Stage
Seed
Founded
2021
Headcount
11
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
Nanocarry is developing therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases. The company’s AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond.
Nanocarry’s first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.
Funding history · 5 rounds · $1.0M total
2021-10
Pre-Seed
Undisclosed
2022-06
Grant
Undisclosed
2024-01
Grant
$1.0M
2024-08
Undisclosed
2025-01
Seed
Undisclosed
Q&A
- What is Nanocarry Therapeutics' primary focus?
- Nanocarry Therapeutics is developing nanoparticle-based therapeutics for brain cancer and central nervous system (CNS) disorders. Their AxS platform is designed to deliver biologics to the brain and other areas.
- When was Nanocarry Therapeutics founded?
- Nanocarry Therapeutics was founded in January 2021.
- How many employees does Nanocarry Therapeutics have?
- Nanocarry Therapeutics has 11-50 employees.
- What was Nanocarry Therapeutics' most recent funding round?
- Nanocarry Therapeutics completed a Seed funding round in January 2025, with NFX Capital as a lead investor.
- Which investors participated in Nanocarry Therapeutics' August 2024 funding round?
- Sapir Venture Partners participated in Nanocarry Therapeutics' funding round in August 2024.
- What grant funding did Nanocarry Therapeutics receive in January 2024?
- In January 2024, Nanocarry Therapeutics received a grant of $1,000,000 from the Israel Innovation Authority.
- Who are the co-founders of Nanocarry Therapeutics?
- The co-founders of Nanocarry Therapeutics are Revital Mandil Levin (Co-founder & CEO), Rachela Popovtzer (Co-founder & CSO), and Oshra Betzer (Co-founder & CTO).
- What types of cancer are Nanocarry Therapeutics' first products in development targeting?
- Nanocarry Therapeutics' first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.
Team · 6
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital TherapeuticsPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2C
Tags
personalized-treatmentmedical-technologiescancertreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nanocarry.com/ |
|---|---|
| linkedin.com/company/76550130 |
Identifiers & details
| Founded | 2021-1 |
|---|---|
| Employees (exact) | 11 |
Radar intelligence
Patents
| EPO | 3 |
|---|
Web history (Wayback)
| Domain | nanocarry.com |
|---|